First-in-human CRISPR therapy safely and continuously lowers cholesterol
garrytan · x · 2026-09-07
Garry Tan shared a Medicalxpress report: a first-in-human trial of a CRISPR gene-editing therapy shows it safely and continuously lowers cholesterol and triglycerides.
A significant clinical milestone for gene editing in cardiometabolic disease, marking the first human-trial evidence of both safety and durable effect.
More from Research
- AI Math Podcast Sits Down With CMU's Jeremy Avigad: Can Mathematics Be Automated? — EchoShao8899 · 2026-09-07
- 'The honest claim' emerges as telltale AI-writing phrase in bioRxiv preprints — lpachter · 2026-09-07
- Is Reproducibility a Lost Cause in ML Research? A Debate — NeighborhoodFatCat · 2026-09-07
- GPT Astra Solves 1962 Erdős–Sós Conjecture in 1 of 3 Tries for $363 — burny_tech · 2026-09-07
- Microsoft Paper: Distilling 50 Trajectories Into Skill Cards Matches Costly Reasoning — rohanpaul_ai · 2026-09-07
- Computer-Use Models Are Still 'Low-Frequency, Highly Batched' — Minecraft May Stay Unsolved Until 2030 — mike64_t · 2026-09-07